Y Intercept Hong Kong Ltd Invests $462,000 in Emergent Biosolutions Inc. (NYSE:EBS)

Y Intercept Hong Kong Ltd acquired a new stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 95,026 shares of the biopharmaceutical company's stock, valued at approximately $462,000. Y Intercept Hong Kong Ltd owned about 0.17% of Emergent Biosolutions at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Covestor Ltd lifted its holdings in Emergent Biosolutions by 5,458.5% in the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 2,893 shares during the period. Northern Trust Corp increased its stake in shares of Emergent Biosolutions by 2.6% during the fourth quarter. Northern Trust Corp now owns 145,889 shares of the biopharmaceutical company's stock valued at $1,395,000 after purchasing an additional 3,692 shares in the last quarter. LPL Financial LLC increased its stake in shares of Emergent Biosolutions by 34.5% during the fourth quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company's stock valued at $145,000 after purchasing an additional 3,875 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Emergent Biosolutions by 40.4% during the first quarter. Bank of New York Mellon Corp now owns 17,003 shares of the biopharmaceutical company's stock valued at $83,000 after purchasing an additional 4,894 shares in the last quarter. Finally, Federated Hermes Inc. increased its stake in shares of Emergent Biosolutions by 2.2% during the fourth quarter. Federated Hermes Inc. now owns 277,810 shares of the biopharmaceutical company's stock valued at $2,656,000 after purchasing an additional 6,058 shares in the last quarter. 78.40% of the stock is owned by institutional investors.

Emergent Biosolutions Stock Down 2.8%

Shares of EBS traded down $0.17 on Friday, hitting $5.72. 453,115 shares of the stock traded hands, compared to its average volume of 1,214,136. The company has a market capitalization of $310.21 million, a PE ratio of -2.11 and a beta of 2.09. The company has a debt-to-equity ratio of 1.20, a quick ratio of 3.51 and a current ratio of 6.32. The business has a 50 day simple moving average of $6.68 and a 200 day simple moving average of $6.81. Emergent Biosolutions Inc. has a one year low of $4.02 and a one year high of $13.28.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.22. Emergent Biosolutions had a negative net margin of 13.63% and a negative return on equity of 0.52%. The company had revenue of $222.20 million during the quarter, compared to the consensus estimate of $218.50 million. As a group, equities analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Emergent Biosolutions news, Director Keith Katkin sold 7,844 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $6.30, for a total value of $49,417.20. Following the completion of the sale, the director owned 86,431 shares of the company's stock, valued at approximately $544,515.30. The trade was a 8.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.20% of the company's stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.